Highlights

  • Q3 2026 net sales were $5.138 billion, up 1.5 percent, with GAAP EPS of $0.40 and adjusted EPS $0.73.
  • The company estimates 2026 adjusted EPS of $3.16 to $3.18 and fourth quarter net sales declining (3.0) to (1.0) percent.
  • The quarter included $81 million of litigation-related charges, $63 million of restructuring charges and $39 million of impairment charges.
  • Management said a cybersecurity incident reduced third quarter sales growth by approximately 300 basis points and adjusted EPS by $0.07.

Boston Scientific (NYSE:BSX) shares were trading at USD 43.50 on October 28, 2026, down 3.47%, with a relative volume at time of 5.92. The medical technology company reported third quarter 2026 results on October 28, 2026, along with updated full-year and fourth quarter guidance and comments on an August 2026 cybersecurity incident.

Boston Scientific Corporation is a Delaware corporation headquartered in Marlborough, Massachusetts. The company describes itself as a global medical technology company that provides devices and therapies to diagnose and treat cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. It reports two segments, MedSurg and Cardiovascular, and net sales across the United States, Europe, Middle East and Africa, Asia-Pacific, and Latin America and Canada. Its common stock and its 0.625% Senior Notes due 2027 are listed on the New York Stock Exchange.

Third Quarter 2026 Results

Net sales for the third quarter ended September 30, 2026 were $5.138 billion, compared with $5,065 million a year earlier, an increase of 1.5 percent on a reported, operational and organic basis. GAAP net income attributable to common stockholders was $582 million, or $0.40 per share, compared with $755 million, or $0.51 per share. Adjusted EPS, a non-GAAP measure, was $0.73, compared with $0.75.

MedSurg net sales were $1,733 million, compared with $1,722 million, and Cardiovascular net sales were $3,406 million, compared with $3,343 million. By region, U.S. net sales were $3,309 million, EMEA $829 million, APAC $797 million and LACA $203 million.

Costs, Charges and Nine-Month Results

Gross profit was $3,428 million, compared with $3,542 million. Operating income was $828 million, compared with $1,048 million. Operating expenses included intangible asset impairment charges of $39 million, restructuring net charges of $63 million and litigation-related net charges of $81 million. Contingent consideration was a net benefit of $32 million. Interest expense was $100 million, compared with $87 million.

For the nine months ended September 30, 2026, net sales were $15,784 million, compared with $14,788 million. Net income attributable to common stockholders was $2,830 million, or $1.92 per diluted share, compared with $2,226 million, or $1.49 per diluted share.

Business Developments

The company commenced enrollment in the Elite AF clinical trial of the next-generation WATCHMAN Elite Left Atrial Appendage Closure Device. It received FDA 510(k) clearance for two technologies within the StoneSmart Solutions ecosystem and for an expanded size offering of the SEISMIQ Intravascular Lithotripsy Peripheral Catheter.

It also recognized the American Medical Association's assignment of Category I CPT codes for renal denervation devices and implantable tibial nerve stimulation devices, effective January 2028. Boston Scientific entered a strategic collaboration with Heartflow, Inc. on CT-guided planning for percutaneous coronary intervention.

On the call, Chairman and Chief Executive Officer Mike Mahoney said operations were back up and running as of September 8 after the cybersecurity incident, which the company first reported on August 26, 2026. Management said it estimated the incident reduced third quarter sales growth by approximately 300 basis points and adjusted EPS by $0.07.

Guidance and Outlook

The company now estimates full-year 2026 net sales growth of approximately 4.25 percent on a reported basis and approximately 3.75 percent on an organic basis. It estimates full-year adjusted EPS of $3.16 to $3.18.

For the fourth quarter of 2026, the company estimates net sales to decline by approximately (3.0) to (1.0) percent on a reported and organic basis, and adjusted EPS of $0.77 to $0.79. The company has not provided GAAP reconciliations of forward-looking adjusted EPS, saying certain charges cannot be predicted with reasonable certainty.

On the call, management said it expects 2027 to be challenging for sales and adjusted EPS growth, excluding its pending acquisition of Penumbra, and pointed to a previously announced restructuring program.